|
15 Sep 2025 |
Dr. Reddy's Labs
|
Consensus Share Price Target
|
1300.80 |
1287.37 |
- |
-1.03 |
hold
|
|
|
|
|
01 Nov 2022
|
Dr. Reddy's Labs
|
Axis Direct
|
1300.80
|
5000.00
|
4535.30
(-71.32%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a TP of Rs 5,000/share.
|
|
31 Oct 2022
|
Dr. Reddy's Labs
|
SMC online
|
1300.80
|
|
4555.65
(-71.45%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
31 Oct 2022
|
Dr. Reddy's Labs
|
ICICI Securities Limited
|
1300.80
|
5134.00
|
4459.95
(-70.83%)
|
Target met |
Buy
|
|
|
Dr. Reddy’s Laboratories’ (DRL) Q2FY23 reported performance exceeded our and consensus estimates, largely driven by strong sales of Revlimid and recovery of US base and Russia sales.
|
|
31 Oct 2022
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1300.80
|
4900.00
|
4535.30
(-71.32%)
|
Target met |
Buy
|
|
|
|
|
29 Oct 2022
|
Dr. Reddy's Labs
|
BOB Capital Markets Ltd.
|
1300.80
|
|
4433.70
(-70.66%)
|
Pre-Bonus/ Split |
Hold
|
|
|
Q2 revenue up 9% YoY on sales of gRevlimid in the US; gross margin expansion aids EBITDA growth of 42% YoY
|
|
29 Oct 2022
|
Dr. Reddy's Labs
|
ICICI Direct
|
1300.80
|
5215.00
|
4459.95
(-70.83%)
|
Target met |
Buy
|
|
|
|
|
29 Oct 2022
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1300.80
|
5180.00
|
4433.70
(-70.66%)
|
Target met |
Buy
|
|
|
|
|
01 Aug 2022
|
Dr. Reddy's Labs
|
SMC online
|
1300.80
|
|
4096.30
(-68.24%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
29 Jul 2022
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1300.80
|
4750.00
|
4110.45
(-68.35%)
|
Target met |
Buy
|
|
|
|
|
29 Jul 2022
|
Dr. Reddy's Labs
|
ICICI Direct
|
1300.80
|
4750.00
|
4090.35
(-68.20%)
|
Target met |
Buy
|
|
|
|